Physician profile
James N Eickholz
NPI 1831120930
$13,711.90
in general payments reported to CMS, 2019-2025
42 companies · $1,769 in 2025
The $1,769 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,949 · 2020: $1,885 · 2021: $1,850 · 2022: $2,293 · 2023: $1,928 · 2024: $2,038 · 2025: $1,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,735.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,542.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,535.44 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,013.88 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $943.83 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $926.96 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $883.43 | 2019-2023 | Jardiance |
| Amgen INC. | $788.76 | 2019-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $778.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $620.03 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $479.85 | 2019-2025 | Trintellix |
| Horizon Therapeutics Plc | $425.23 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $339.54 | 2019-2021 | |
| Allergan, INC. | $252.79 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $241.36 | 2019-2025 | Camzyos, Eliquis |
| Sumitomo Pharma America, INC. | $206.24 | 2023-2025 | Gemtesa |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $182.16 | 2021-2025 | |
| Ironshore Pharmaceuticals INC. | $144.75 | 2019-2020 | |
| Axsome Therapeutics, INC. | $136.49 | 2022-2025 | Auvelity, Symbravo |
| Astellas Pharma US INC | $124.52 | 2023-2024 | Myrbetriq, Veozah |
| Exact Sciences Corporation | $116.67 | 2023-2025 | Cologuard Collection Kit |
| Biogen, INC. | $103.26 | 2021-2022 | |
| Dexcom, INC. | $99.59 | 2023-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $89.07 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $83.14 | 2022 | |
| Abbott Laboratories | $77.28 | 2023-2025 | Proclaim, Ensite Precision, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $71.60 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.97 | 2023-2025 | Xifaxan |
| Shire North American Group INC | $65.70 | 2019 | |
| Pfizer INC. | $62.02 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $60.88 | 2021 | |
| Inari Medical, INC. | $39.26 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Glaxosmithkline, LLC. | $31.67 | 2019-2024 | Trelegy Ellipta |
| Medtronic, INC. | $28.29 | 2024 | Intellis Adaptivestim |
| Inspire Medical Systems, INC. | $19.15 | 2024 | Inspire |
| Otsuka America Pharmaceutical, INC. | $18.70 | 2023 | Rexulti |
| Azurity Pharmaceuticals, INC. | $18.66 | 2024 | Edarbi |
| Sunovion Pharmaceuticals INC. | $17.45 | 2022 | |
| Tris Pharma INC | $16.52 | 2023 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $15.77 | 2019 | |
| Esperion Therapeutics, INC. | $15.60 | 2024 | Nexletol |
| Tactile Systems Technology INC | $13.38 | 2019 | |
| Zyla Life Sciences, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Eickholz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.